– Concept amplifies impact of diagnostics to help improve patient management – Integrates connected core lab with automation, IT solutions, analytics and tests with high medical value The Roche booth at the 2017 AACC Clinical Lab Expo will feature a virtual reality experience that allows attendees to take a self-guided tour through three types of... Read more
Basel, 28 July 2017 FDA grants breakthrough therapy designation for Venclexta in acute myeloid leukaemia First in class BCL2-specific oral inhibitor represents a potential new way of treating acute myeloid leukaemia (AML), the most common type of aggressive leukaemia in adults1 17th breakthrough therapy designation for Roche’s portfolio of medicines and 4th for Venclexta Roche... Read more
Basel, 21 July 2017 Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis If approved, Actemra/RoActemra would be the first therapy for the treatment of giant cell arteritis (GCA) in Europe GCA can lead to blindness, aortic aneurysm or stroke if left untreated The positive opinion is based on the outcome... Read more
Basel, 21 July 2017 CHMP recommends EU approval of Roche’s Gazyvaro for people with previously untreated advanced follicular lymphoma Pivotal GALLIUM study demonstrated that Gazyvaro-based treatment helped people with previously untreated follicular lymphoma live significantly longer without disease progression compared to MabThera-based treatment Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the EU Committee... Read more
Basel, 21 July 2017 CHMP recommends EU approval of Roche’s Gazyvaro for people with previously untreated advanced follicular lymphoma Pivotal GALLIUM study demonstrated that Gazyvaro-based treatment helped people with previously untreated follicular lymphoma live significantly longer without disease progression compared to MabThera-based treatment Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the EU Committee... Read more
Basel, 21 July 2017 CHMP recommends EU approval for Roche’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential treatment option for people with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) TECENTRIQ as a potential treatment option for people with... Read more
Basel, 21 July 2017 CHMP recommends EU approval for Roche’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential treatment option for people with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) TECENTRIQ as a potential treatment option for people with... Read more
Basel, 18 July 2017 Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2017 Tuesday, 1st August 2017, 6:00pm PDT We are pleased to invite you to an analyst event on Tuesday, 1st August 2017 to discuss Roche’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and... Read more
Basel, 17 July 2017 Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and only approved treatment for people with primary progressive multiple sclerosis, a highly disabling form of MS Australia has among the highest prevalence of MS in the Southern... Read more
Basel, 17 July 2017 Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and only approved treatment for people with primary progressive multiple sclerosis, a highly disabling form of MS Australia has among the highest prevalence of MS in the Southern... Read more